Sevilay Altintas
Edegem, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Beyond recurrence detection: Treating the forgotten menopause in endometrial cancer survivors.
Journal: European journal of obstetrics, gynecology, and reproductive biology
Published: December 22, 2025
Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.
Journal: Journal of hematology & oncology
Published: March 20, 2025
Dynamics of SERPINA3 in response to anthracycline treatment and cardiovascular dysfunction.
Journal: Cardio-oncology (London, England)
Published: December 28, 2024
Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy?
Journal: Breast (Edinburgh, Scotland)
Published: December 25, 2024
NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.
Journal: Gynecologic oncology
Published: November 14, 2024
Atherosclerosis after pre-eclampsia: systematic review and meta-analysis.
Journal: Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
Published: September 29, 2024
Tumor Microenvironment Modulation by Tumor-Associated Macrophages: Implications for Neoadjuvant Chemotherapy Response in Breast Cancer.
Journal: Breast cancer (Dove Medical Press)
Published: September 11, 2024
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.
Journal: Journal of hematology & oncology
Published: August 26, 2024
The immune microenvironment characterisation and dynamics in hormone receptor-positive breast cancer before and after neoadjuvant endocrine therapy.
Journal: Cancer medicine
Published: November 05, 2022
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: November 02, 2022
Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion.
Journal: Facts, views & vision in ObGyn
Published: July 05, 2022
Last Updated: 09/26/2026